<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="case-report" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id>
<journal-title>Frontiers in Immunology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Immunol.</abbrev-journal-title>
<issn pub-type="epub">1664-3224</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fimmu.2023.1201163</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Immunology</subject>
<subj-group>
<subject>Case Report</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Case Report: Prurigo nodularis-like linear IgA/IgG bullous dermatosis: a case report and literature review</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Yuxi</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2095951"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Xingli</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2055775"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Xun</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2087616"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Xia</surname>
<given-names>Dengmei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn002">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1925655"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Qian</surname>
<given-names>Hua</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2236920"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Hongjie</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Xiaoguang</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/651623"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1895194"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of Dermatology &amp; Venerology, Rare Diseases Center, West China Hospital, Sichuan University</institution>, <addr-line>Chengdu, Sichuan</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Laboratory Medicine, Chronic Disease Research Center, Medical College, Dalian University</institution>, <addr-line>Dalian</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Takashi Hashimoto, Osaka City University, Japan</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Emiliano Antiga, University of Florence, Italy; Andreas Recke, University of L&#xfc;beck, Germany</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Wei Li, <email xlink:href="mailto:liweihx_hxyy@scu.edu.cn">liweihx_hxyy@scu.edu.cn</email>; Xiaoguang Li, <email xlink:href="mailto:liqian0041@139.com">liqian0041@139.com</email>
</p>
</fn>
<fn fn-type="present-address" id="fn002">
<p>&#x2020;Present address: Dengmei Xia, Department of Dermatology, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan, China</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>30</day>
<month>05</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>14</volume>
<elocation-id>1201163</elocation-id>
<history>
<date date-type="received">
<day>06</day>
<month>04</month>
<year>2023</year>
</date>
<date date-type="accepted">
<day>19</day>
<month>05</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Zhou, Zhou, Feng, Xia, Qian, Liu, Li and Li</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Zhou, Zhou, Feng, Xia, Qian, Liu, Li and Li</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<p>Linear IgA/IgG bullous dermatosis (LAGBD) is a rare autoimmune subepidermal bullous disorder characterized by linear deposition of concurrent IgA and IgG autoantibodies along the basement membrane zone (BMZ). The clinical features of LAGBD can be diverse, including tense blisters, erosions, erythema, crusting and mucosa involvement, while papules or nodules are generally absent. In this study, we present a unique case of LAGBD, which showed prurigo nodularis-like clinical appearance on physical examination, linear deposition of IgG and C3 along the basement membrane zone (BMZ) in direct immunofluorescence (DIF), IgA autoantibodies against the 97-kDa and 120-kDa of BP180 and IgG autoantibodies against the 97-kDa of BP180 by immunoblotting (IB), while BP180 NC16a domain, BP230, and laminin 332 were negative by enzyme-linked immunosorbent assay (ELISA). After administration of minocycline, the skin lesions improved. We performed a literature review of LAGBD cases with heterogeneous autoantibodies and found clinical presentations of most cases resemble bullous pemphigoid (BP) and linear IgA bullous disease (LABD), which is consistent with previous reported findings. We aim to increase our understanding of this disorder and to enhance the importance of applying immunoblot analyses and other serological detection tools in clinic for precise diagnosis as well as accurate treatment strategy of various autoimmune bullous dermatoses.</p>
</abstract>
<kwd-group>
<kwd>differential diagnosis</kwd>
<kwd>heterogenous</kwd>
<kwd>linear IgA/IgG bullous dermatosis</kwd>
<kwd>prurigo nodularis</kwd>
<kwd>autoantibody</kwd>
</kwd-group>
<counts>
<fig-count count="3"/>
<table-count count="1"/>
<equation-count count="0"/>
<ref-count count="15"/>
<page-count count="5"/>
<word-count count="1553"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-in-acceptance</meta-name>
<meta-value>Autoimmune and Autoinflammatory Disorders : Autoimmune Disorders</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Subepidermal autoimmune bullous dermatoses comprise a group of skin disorders characterized by autoantibodies against epidermal basement membrane zone (BMZ) proteins, which include bullous pemphigoid (BP), linear IgA bullous disease (LABD), mucous membrane pemphigoid (MMP) and others (<xref ref-type="bibr" rid="B1">1</xref>). Linear IgA/IgG bullous dermatosis (LAGBD) is a rare autoimmune bullous disease, which was first proposed and termed in 1994 by Zone and others in order to identify a unique condition on the basis of immunopathologic findings (<xref ref-type="bibr" rid="B2">2</xref>). Cutaneous lesions of LAGBD are often variable and can mimic those of other autoimmune bullous dermatoses such as BP and LABD (<xref ref-type="bibr" rid="B3">3</xref>). Prurigo nodularis is a unique response pattern that occurs in some patients with chronic pruritus due to prolonged scratching (<xref ref-type="bibr" rid="B4">4</xref>).</p>
<p>In this case report we describe an unusual case of LAGBD clinically resembling prurigo nodularis and performed a review of reported cases of LAGBD with heterogeneous autoantibodies. This report aims to raise dermatologists&#x2019; awareness of this rare disease and since there is no clear diagnostic criteria for LAGBD at present, the presentation of our study is expected to have some positive influence on the proposal of the diagnostic criteria of this disease.</p>
</sec>
<sec id="s2">
<title>Case presentation</title>
<p>An 81-year-old Chinese male was referred to our outpatient clinic and complained of a 10-year history of widespread pruritic vesiculobullous lesions on his trunk and extremities. He had initially been diagnosed with eczema and treated with topical corticosteroids without obvious improvement at a local clinic. No other significant medical, family, psychosocial, genetic or past history were elicited. Physical examination revealed numerous papules and nodules present on the trunk and extremities along with many hemorrhagic crusted erosions and hyperpigmented macules (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1A&#x2013;C</bold>
</xref>). No signs of any mucosal involvement were found. Biopsy from the back demonstrated focal spongiosis in the stratum spinosum and focal vacuolar degeneration in the basal lamina. Mixed inflammatory cells infiltrated around small vessels in the dermis (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2A</bold>
</xref>). Direct immunofluorescence (DIF) revealed linear deposition of IgG (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2C</bold>
</xref>) and C3 (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2D</bold>
</xref>) and absent IgA (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2B</bold>
</xref>) along the BMZ. Indirect immunofluorescence on human salt-split skin was negative. Immunoblotting (IB) using epidermal extracts showed IgA antibodies reacted with 97-kDa and 120-kDa of BP180 and that IgG antibodies reacted with 97-kDa of BP180, while showed no antibodies against 290-kDa type VII collagen and laminin-&#x3b3;1 in the extracts of dermis (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>). BP180 NC16a domain, BP230, and laminin 332 were negative by enzyme-linked immunosorbent assay (ELISA). On the basis of the above findings, we diagnosed the patient as LAGBD. He was treated with oral minocycline (100 mg/day), and topical halometasone ointment once daily. After one-month follow-up, new skin lesions ceased to form, re-epithelialization was observed in most erosions, and pruritus improved significantly (<xref ref-type="fig" rid="f1">
<bold>Figures&#xa0;1D&#x2013;F</bold>
</xref>). Bullous pemphigoid disease area index (BPDAI) score decreased from 25 to 14. Unfortunately, he was eventually lost following up due to the COVID-19 pandemic.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Clinical manifestations of this patient. The clinical features on the back <bold>(A, D)</bold>, posterior side of both lower limbs <bold>(B, E)</bold> and right thigh <bold>(C, F)</bold> at Day 0 and Day30 are shown.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1201163-g001.tif"/>
</fig>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Results of histopathological and direct immunofluorescence. <bold>(A)</bold> Histopathological features of biopsy from lesioned skin on the back (HE staining, original magnification, &#xd7;100). <bold>(B&#x2013;D)</bold> Direct immunofluorescence (DIF) for IgA <bold>(B)</bold>, IgG <bold>(C)</bold> and C3 <bold>(D)</bold>.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1201163-g002.tif"/>
</fig>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Immunoblotting analysis of normal epidermal extracts. Lane 1, bullous pemphigoid (BP) control serum, which is positive for autoantibodies against BP180 and 120kDa-BP180. Lane 2 and 3, patient serum, which is positive for IgG (lane 2) autoantibodies against 97kDa-BP180, and IgA (lane 3) autoantibodies against both 120kDa-BP180 and 97kDa-BP180.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fimmu-14-1201163-g003.tif"/>
</fig>
</sec>
<sec id="s3" sec-type="discussion">
<title>Discussion</title>
<p>We report an atypical case of an 81-year-old man suffering from LAGBD that clinically resembled prurigo nodularis. In this study, we adopt the statement that the diagnosis of LAGBD is based on the serological detection of concurrent IgA and IgG autoantibodies against BP180 according to the algorithm in a study of 4774 cases with autoimmune bullous disease (<xref ref-type="bibr" rid="B5">5</xref>) and review the reported cases of LAGBD with heterogenous autoantibodies detected by IB or ELISA (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). So far, LAGBD has been reported to present a variety of clinical features (<xref ref-type="bibr" rid="B3">3</xref>). From <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>, a majority of patients presented with blisters, erosions, and erythema, whereas in the present case, physical examination showed numerous papules and nodules present on the whole body and nodular formation was predominant. Ohata et&#xa0;al. described in a clinical and serological study of 101 patients with LABD that 5 patients with LAGBD presented with prurigo-like eruptions (<xref ref-type="bibr" rid="B15">15</xref>). However, it was not mentioned in the article whether the skin lesions of these 5 patients presented mainly nodules.</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Cases of linear IgA/IgG bullous dermatosis with heterogenous autoantibodies.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left" rowspan="2">Author/year</th>
<th valign="middle" align="left" rowspan="2">country</th>
<th valign="middle" align="left" rowspan="2">Age (years)/sex</th>
<th valign="middle" align="left" rowspan="2">Clinical features</th>
<th valign="middle" align="left" rowspan="2">Mucous lesions</th>
<th valign="middle" colspan="3" align="left">DIF(BMZ)</th>
<th valign="middle" colspan="2" align="left">ss-IIF</th>
<th valign="middle" align="left" rowspan="2">Antigen</th>
</tr>
<tr>
<th valign="middle" align="left">IgA</th>
<th valign="middle" align="left">IgG</th>
<th valign="middle" align="left">C3</th>
<th valign="middle" align="left">IgG</th>
<th valign="middle" align="left">IgA</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">Palmer R et&#xa0;al./2001 (<xref ref-type="bibr" rid="B6">6</xref>)</td>
<td valign="middle" align="left">U.K.</td>
<td valign="middle" align="left">86/F</td>
<td valign="middle" align="left">Bullae, erosions</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">LAD285</td>
</tr>
<tr>
<td valign="middle" align="left">Osawa M, et&#xa0;al./2005 (<xref ref-type="bibr" rid="B7">7</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">75/M</td>
<td valign="middle" align="left">Bullae, ulcers</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">D+</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">LAD-1</td>
</tr>
<tr>
<td valign="middle" align="left">Sakaguchi M, et&#xa0;al./2013 (<xref ref-type="bibr" rid="B8">8</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">81/F</td>
<td valign="middle" align="left">Blisters, erosions, erythemas</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">E+,D+</td>
<td valign="middle" align="left">E+,D+</td>
<td valign="middle" align="left">TypeVII collagen</td>
</tr>
<tr>
<td valign="middle" align="left">Izaki S, et&#xa0;al./2015 (<xref ref-type="bibr" rid="B9">9</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">53/M</td>
<td valign="middle" align="left">Erythemas, bullae, erosions, pustules, crusts, scales</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">D+</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">laminin-332</td>
</tr>
<tr>
<td valign="middle" align="left">LiX, et&#xa0;al./2015 (<xref ref-type="bibr" rid="B10">10</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">74/M</td>
<td valign="middle" align="left">Erythemas, blisters, erosions, pustules</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">E+,D+</td>
<td valign="middle" align="left">E+,D+</td>
<td valign="middle" align="left">integrin</td>
</tr>
<tr>
<td valign="middle" align="left">Hashimoto T, et&#xa0;al./2018 (<xref ref-type="bibr" rid="B11">11</xref>)</td>
<td valign="middle" align="left">USA</td>
<td valign="middle" align="left">11/M</td>
<td valign="middle" align="left">Not mention</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">Dsg1,3</td>
</tr>
<tr>
<td valign="middle" align="left">Matsudate Y, et&#xa0;al./2019 (<xref ref-type="bibr" rid="B12">12</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">87/M</td>
<td valign="middle" align="left">Erythemas, blisters, erosions,</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">E+D+</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">laminin-yl</td>
</tr>
<tr>
<td valign="middle" align="left">Matsumoto T, et&#xa0;al./2019 (<xref ref-type="bibr" rid="B13">13</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">82/M</td>
<td valign="middle" align="left">Erythemas</td>
<td valign="middle" align="left">Not mention</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">BP230</td>
</tr>
<tr>
<td valign="middle" align="left">Inamura E, et&#xa0;al./2020 (<xref ref-type="bibr" rid="B14">14</xref>)</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">69/M</td>
<td valign="middle" align="left">Blisters,vesicles, erythemas, crusts</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">+</td>
<td valign="middle" align="left">&#x2013;</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">E+</td>
<td valign="middle" align="left">full-length BP180</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Initially, this patient&#x2019;s symptoms suggested the possibility of pemphigoid nodularis because the itchy nodules were predominant and DIF revealed linear deposition of IgG and C3 along the BMZ. However, as a rare clinical variant of BP, pemphigoid nodularis is commonly associated with anti-BP230 antibodies. And the NC16A domain of BP180 (NC16A-BP180) can also be detected via ELISA (<xref ref-type="bibr" rid="B1">1</xref>), whereas in our case, these antibodies show negative in ELISA but IgA autoantibody against BP180 was detected via IB, supporting the diagnosis of LAGBD with prurigo-nodularis appearance rather than pemphigoid nodularis. At present the mechanism that determines the prurigo nodularis-like eruptions still remains unknow. With regard to other differential diagnoses, linear IgA deposition along the BMZ may also be encountered in mucous membrane pemphigoid (MMP) and epidermolysis bullosa dermatosis (EBA) (<xref ref-type="bibr" rid="B1">1</xref>). However, the oral mucosa and ocular conjunctiva are most commonly affected in MMP patients and severe complications such as blindness and esophageal stenosis can be caused by scarring. But our case does not show any sign of mucosa involvement. Besides, in EBA, type VII collagen can be detected via ELISA, which showed negative in our case.</p>
<p>In LAGBD, IgA and IgG anti-BP180 antibodies appear most often (<xref ref-type="bibr" rid="B3">3</xref>). In our case, IB using epidermal extracts showed IgA antibodies reacted with 97-kDa and 120-kDa of BP180 and that IgG antibodies reacted with 97-kDa of BP180. A few other weak protein bands such as the 190-kDa protein (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>) were also observed in the serum lanes of this patient. However, due to the very weak reactivity of these bands, we considered them to be nonspecific. This may be explained by an epitope-spreading phenomenon. To date, other antibodies have been reported in the previous literatures, confirming the heterogenous nature of this disorder. Among these findings from <xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>, although IgA or IgG anti-BMZ antibodies of some cases are negative in DIF, over half of the patients had IgA or IgG antibodies detected either by IIF, IB or ELISA. Hence, the proportion may increase if IB and ELISA can be applied extensively to detect IgA or IgG anti-BMZ antibodies in the future.</p>
<p>To conclude, this is a rare case of LAGBD with prurigo nodularis-like eruptions. Prurigo nodularis is considered to be caused by chronic itch followed by repeated and prolonged scratching (<xref ref-type="bibr" rid="B4">4</xref>). In this case, skin lesions presented mainly with nodules, and we hypothesize this may be associated with the patient&#x2019;s severe itch and prolonged excoriation. Therefore, serological techniques to detect autoantibodies are suggested when confronted with patients with prurigo-like lesions in clinic. The causative factors for the unique clinical presentation of our case currently remain unknown. Due to the limited clinical data in this review, further similar cases are needed to elucidate this disease.</p>
</sec>
<sec id="s4" sec-type="data-availability">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.</p>
</sec>
<sec id="s5" sec-type="ethics-statement">
<title>Ethics statement</title>
<p>Written informed consent was obtained from the individual(s) for the publication of any potentially identifiable images or data included in this article.</p>
</sec>
<sec id="s6" sec-type="author-contributions">
<title>Author contributions</title>
<p>WL designed this project and revised this manuscript. YZ, XZ, XF, and DX contributed to collect case information and prepare the manuscript. HL was responsible for histopathology support. HQ and XL collected laboratory data and analyzed the data. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s7" sec-type="funding-information">
<title>Funding</title>
<p>1&#xb7;3&#xb7;5 project for disciplines of excellence, West China Hospital, Sichuan University (Grant. ZYJC21050).</p>
</sec>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Montagnon</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Tolkachjov</surname> <given-names>SN</given-names>
</name>
<name>
<surname>Murrell</surname> <given-names>DF</given-names>
</name>
<name>
<surname>Camilleri</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>Lehman</surname> <given-names>JS</given-names>
</name>
</person-group>. <article-title>Subepithelial autoimmune blistering dermatoses: clinical features and diagnosis</article-title>. <source>J Am Acad Dermatol</source> (<year>2021</year>) <volume>85</volume>(<issue>1</issue>):<fpage>1</fpage>&#x2013;<lpage>14</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2020.11.076</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zone</surname> <given-names>J</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>EP</given-names>
</name>
<name>
<surname>Powell</surname> <given-names>D</given-names>
</name>
<name>
<surname>Taylor</surname> <given-names>T</given-names>
</name>
<name>
<surname>Smith</surname> <given-names>J</given-names>
</name>
<etal/>
</person-group>. <article-title>Antigenic specificity of antibodies from patients with linear basement membrane deposition of IgA</article-title>. <source>Dermatology</source> (<year>1994</year>) <volume>189</volume>(<supplement>Suppl. 1</supplement>):<page-range>64&#x2013;6</page-range>. doi: <pub-id pub-id-type="doi">10.1159/000246933</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nedosekin</surname> <given-names>D</given-names>
</name>
<name>
<surname>Wilson</surname> <given-names>KD</given-names>
</name>
<name>
<surname>Campbell</surname> <given-names>K</given-names>
</name>
<name>
<surname>Shalin</surname> <given-names>S</given-names>
</name>
<name>
<surname>Wong</surname> <given-names>HK</given-names>
</name>
</person-group>. <article-title>Immunologic overlap in a case of linear IgG/IgA bullous dermatosis responsive to rituximab</article-title>. <source>JAAD Case Rep</source> (<year>2021</year>) <volume>9</volume>:<fpage>57</fpage>&#x2013;<lpage>60</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jdcr.2020.12.029</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname> <given-names>KA</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>AH</given-names>
</name>
<name>
<surname>Belzberg</surname> <given-names>M</given-names>
</name>
<name>
<surname>Kwatra</surname> <given-names>SG</given-names>
</name>
</person-group>. <article-title>Prurigo nodularis: pathogenesis and management</article-title>. <source>J Am Acad Dermatol</source> (<year>2020</year>) <volume>83</volume>(<issue>6</issue>):<page-range>1567&#x2013;75</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jaad.2020.04.182</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tsuruta</surname> <given-names>D</given-names>
</name>
<name>
<surname>Koga</surname> <given-names>H</given-names>
</name>
<name>
<surname>Fukuda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ohyama</surname> <given-names>B</given-names>
</name>
<name>
<surname>Komai</surname> <given-names>A</given-names>
</name>
<etal/>
</person-group>. <article-title>Summary of results of serological tests and diagnoses for 4774 cases of various autoimmune bullous diseases consulted to kurume university</article-title>. <source>Br J Dermatol</source> (<year>2016</year>) <volume>175</volume>(<issue>5</issue>):<page-range>953&#x2013;65</page-range>. doi: <pub-id pub-id-type="doi">10.1111/bjd.14692</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Palmer</surname> <given-names>R</given-names>
</name>
<name>
<surname>Ogg</surname> <given-names>G</given-names>
</name>
<name>
<surname>Allen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Banerjee</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ryatt</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ratnavel</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Vancomycin-induced linear IgA disease with autoantibodies to BP180 and LAD285</article-title>. <source>Br J Dermatol</source> (<year>2001</year>) <volume>145</volume>(<issue>5</issue>):<page-range>816&#x2013;20</page-range>. doi: <pub-id pub-id-type="doi">10.1046/j.1365-2133.2001.04492.x</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Osawa</surname> <given-names>M</given-names>
</name>
<name>
<surname>Demitsu</surname> <given-names>T</given-names>
</name>
<name>
<surname>Toda</surname> <given-names>S</given-names>
</name>
<name>
<surname>Yokokura</surname> <given-names>H</given-names>
</name>
<name>
<surname>Umemoto</surname> <given-names>N</given-names>
</name>
<name>
<surname>Yamada</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>A case of mixed bullous disease of epidermolysis bullosa acquisita and linear IgA bullous dermatosis</article-title>. <source>Dermatology</source> (<year>2005</year>) <volume>211</volume>(<issue>2</issue>):<page-range>146&#x2013;8</page-range>. doi: <pub-id pub-id-type="doi">10.1159/000086445</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakaguchi</surname> <given-names>M</given-names>
</name>
<name>
<surname>Bito</surname> <given-names>T</given-names>
</name>
<name>
<surname>Oda</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Kikusawa</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nishigori</surname> <given-names>C</given-names>
</name>
<name>
<surname>Munetsugu</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Three cases of linear IgA/IgG bullous dermatosis showing IgA and IgG reactivity with multiple antigens, particularly laminin-332</article-title>. <source>JAMA Dermatol</source> (<year>2013</year>) <volume>149</volume>(<issue>11</issue>):<page-range>1308&#x2013;13</page-range>. doi: <pub-id pub-id-type="doi">10.1001/jamadermatol.2013.5691</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Izaki</surname> <given-names>S</given-names>
</name>
<name>
<surname>Mitsuya</surname> <given-names>J</given-names>
</name>
<name>
<surname>Okada</surname> <given-names>T</given-names>
</name>
<name>
<surname>Koga</surname> <given-names>H</given-names>
</name>
<name>
<surname>Hashimoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Terui</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>A case of linear IgA/IgG bullous dermatosis with anti-laminin-332 autoantibodies</article-title>. <source>Acta Derm Venereol</source> (<year>2015</year>) <volume>95</volume>(<issue>3</issue>):<page-range>359&#x2013;60</page-range>. doi: <pub-id pub-id-type="doi">10.2340/00015555-1923</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname> <given-names>X</given-names>
</name>
<name>
<surname>Tsuchisaka</surname> <given-names>A</given-names>
</name>
<name>
<surname>Qian</surname> <given-names>H</given-names>
</name>
<name>
<surname>Teye</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ishii</surname> <given-names>N</given-names>
</name>
<name>
<surname>Sogame</surname> <given-names>R</given-names>
</name>
<etal/>
</person-group>. <article-title>Linear IgA/IgG bullous dermatosis reacts with multiple laminins and integrins</article-title>. <source>Eur J Dermatol</source> (<year>2015</year>) <volume>25</volume>:<page-range>418&#x2013;23</page-range>. doi: <pub-id pub-id-type="doi">10.1684/ejd.2015.2555</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hashimoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Teye</surname> <given-names>K</given-names>
</name>
<name>
<surname>Hashimoto</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wozniak</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ueo</surname> <given-names>D</given-names>
</name>
<name>
<surname>Fujiwara</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Clinical and immunological study of 30 cases with both IgG and IgA anti-keratinocyte cell surface autoantibodies toward the definition of intercellular IgG/IgA dermatosis</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>994</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.00994</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsudate</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Yamasaki</surname> <given-names>K</given-names>
</name>
<name>
<surname>Ujiie</surname> <given-names>H</given-names>
</name>
<name>
<surname>Iwata</surname> <given-names>H</given-names>
</name>
<name>
<surname>Kubo</surname> <given-names>Y</given-names>
</name>
</person-group>. <article-title>Linear immunoglobulin a/immunoglobulin G bullous dermatosis with autoantibodies to LAD-1 and laminin-&#x3b3;1</article-title>. <source>Clin Exp Dermatol</source> (<year>2019</year>) <volume>44</volume>(<issue>3</issue>):<page-range>e44&#x2013;e6</page-range>. doi: <pub-id pub-id-type="doi">10.1111/ced.13921</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matsumoto</surname> <given-names>T</given-names>
</name>
<name>
<surname>Nakamura</surname> <given-names>S</given-names>
</name>
<name>
<surname>Ishii</surname> <given-names>N</given-names>
</name>
<name>
<surname>Umemoto</surname> <given-names>N</given-names>
</name>
<name>
<surname>Kawase</surname> <given-names>M</given-names>
</name>
<name>
<surname>Demitsu</surname> <given-names>T</given-names>
</name>
<etal/>
</person-group>. <article-title>Erythrodermic linear IgA/IgG bullous dermatosis</article-title>. <source>Eur J Dermatol</source> (<year>2019</year>) <volume>29</volume>(<issue>2</issue>):<page-range>220&#x2013;1</page-range>.</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Inamura</surname> <given-names>E</given-names>
</name>
<name>
<surname>Nishie</surname> <given-names>W</given-names>
</name>
<name>
<surname>Yamaguchi</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Fujimura</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Ujiie</surname> <given-names>H</given-names>
</name>
<name>
<surname>Natsuga</surname> <given-names>K</given-names>
</name>
<etal/>
</person-group>. <article-title>Linear IgA/IgG bullous dermatosis with autoantibodies directing the native and processed forms of BP180</article-title>. <source>Br J Dermatol</source> (<year>2020</year>) <volume>182</volume>(<issue>4</issue>):<page-range>1061&#x2013;2</page-range>. doi: <pub-id pub-id-type="doi">10.1111/bjd.18642</pub-id>
</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ohata</surname> <given-names>C</given-names>
</name>
<name>
<surname>Ishii</surname> <given-names>N</given-names>
</name>
<name>
<surname>Koga</surname> <given-names>H</given-names>
</name>
<name>
<surname>Nakama</surname> <given-names>T</given-names>
</name>
</person-group>. <article-title>A clinical and serological study of linear IgA bullous dermatosis without linear immunoglobulin deposition other than IgA at the basement membrane zone using direct immunofluorescence</article-title>. <source>Br J Dermatol</source> (<year>2017</year>) <volume>177</volume>(<issue>1</issue>):<page-range>152&#x2013;7</page-range>. doi: <pub-id pub-id-type="doi">10.1111/bjd.15232</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>